Open Access24‐Hour Efficacy and Safety of Triple‐Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy
Author(s) -
Izzo Jr Joseph L.,
Chrysant Steven G.,
Kereiakes Dean J.,
Littlejohn III Thomas,
Oparil Suzanne,
Melino Michael,
Lee James,
Fernandez Victor,
Heyrman Reinilde
Publication year - 2011
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2011.00544.x
Subject(s) - medicine , olmesartan , hydrochlorothiazide , amlodipine , ambulatory , ambulatory blood pressure , blood pressure , pharmacology , cardiology
J Clin Hypertens (Greenwich) . 2011;13:873–880. ©2011 Wiley Periodicals, Inc. This 12‐week, multicenter, randomized, double‐blinded, 4‐arm study in 440 patients with moderate to severe hypertension compared ambulatory blood pressure (ABP) responses with a triple‐combination regimen (olmesartan medoxomil [OM] 40 mg, amlodipine besylate [AML] 10 mg, and hydrochlorothiazide [HCTZ] 25 mg) and its component dual‐combination regimens at similar doses. At week 12, the triple combination resulted in a greater reduction in mean 24‐hour systolic and diastolic blood pressure (−30.3/−18.0 mm Hg) compared with the 3 dual‐combination regimens (OM 40 mg/AML 10 mg: −23.5/−13.9, OM 40 mg/HCTZ 25 mg: −23.9/−14.5, and AML 10 mg/HCTZ 25 mg: −18.5 mm Hg/−10.7 mm Hg; P<.0001 each). Greater efficacy was also found during daytime and nighttime hours and during the last 6, 4, or 2 hours of the dosing interval. The authors conclude that the triple combination of OM 40 mg/AML 10 mg/HCTZ 25 mg demonstrated superior efficacy and sustained reductions in ABP compared with its dual‐combination components.